Vitalhub Crosses $100M ARR and Adds Buddy Healthcare — A Sharper, AI-Inflected Growth Story
The health-tech consolidator hits a milestone, integrates its acquisitions, and bets on AI scribing and referral management to compound organic growth.
VHI.TO · Earnings Call · 2026-08-07
The $100M Milestone
When Brian Goffenberg opened the call with “Vitalhub reached a new milestone this quarter exceeding $100 million of annual recurring revenue” — Brian Goffenberg, CFO · 2026-08-07 and closed at $101.5 million, it was more than a number. Dan Matlow, the CEO, reflected on the journey:
I think when we started this 8, 9 years ago, that was a goal, and it's achieved.
The organic growth rate of 10% year-over-year, while not explosive, was steady and accelerating against a base that has been broadened by recent acquisitions. The Buddy acquisition – completed days after quarter end – adds roughly $4.5 million of pro forma ARR, pushing initial run-rate to about $106 million.
More striking than the ARR number was the operating leverage. Adjusted EBITDA came in at $8.2 million (26% of revenue), up from $6.3 million a year earlier. The company has guided toward the "high 20s" EBITDA margin, and the sequential improvement – from 26% in Q1 to 26% again in Q2 – shows the integration of Induction and Novari is delivering. As Dan put it, “We're really happy with some of the AI progressions we've built in our team.” — Daniel Matlow, CEO · 2026-08-07 That, combined with a based solutions approach, is starting to show up in the financials.
Buddy Healthcare and the Cross-Sell Thesis
The acquisition of Buddy Healthcare – a patient engagement platform popular in the Nordics and Germany – fills a critical gap. Vitalhub's existing STRATA solution handles the referral and discharge process, but the "digital backdoor" of post-discharge patient communication was missing. Dan explained: “So we're starting to see the behavior that we want in the test for those referral based products.” — Daniel Matlow, CEO · 2026-08-07 His plan is to integrate Buddy's engagement app with Strata and Novari, creating a continuous patient journey. The company already has 20 hospices on Strata in the U.K., and is now rolling out the patient-engagement overlay to those accounts.
The U.K. market is a focus. Despite some headwinds from the Palantir situation (the NHS's national contract has a break clause in Q1 2027), Dan sees momentum: “Even if the contracts are new, we still think there's opportunity to continue.” — Daniel Matlow, CEO · 2026-08-07 The Mental Health segment, where Novari already has a strong footprint, is a key cross-sell target. The recent wins in the U.K. have been in medical health, and the pipeline suggests more to come.
The Nordics region is also an interesting new frontier. Buddy's CEO, who rolled over equity, is helping Vitalhub explore complementary targets there. As Dan said, “Every time we enter a new marketplace, we get expertise on that market and how that ecosystem works and what the gaps are.” — Daniel Matlow, CEO · 2026-08-07
AI and the Next Act
Vitalhub is not sitting still on innovation. The AI products are already contributing: the protocoling solution has helped close two Novari deals, and the company is building its own scribing solution for community and social service clinicians. Dan noted that they have “a fair amount of users between our 4 or 5 products in that suite” who could adopt it, and expects revenue in 2027. The transcription side is the “lowest hanging fruit.” This is a deliberate push to embed AI into every product, from clinical decision support to patient engagement.
What's notable is that Vitalhub is funding this AI investment while improving EBITDA margins. The company's strong cash position – over $120 million post-Buddy – provides a buffer. Dan said, “We are seeing more and more organizations that have had investments of some sort where there's no more cash to be had.” — Daniel Matlow, CEO · 2026-08-07 That pipeline is fueling M&A, but also the recently announced NCIB (buyback).
NCIB and Capital Allocation
Dan was candid about the buyback: “If the shares are still kind of at these levels, you'll be active with the buyback.” — Daniel Matlow, CEO · 2026-08-07 The NCIB allows repurchase of up to 5% of shares, and given the stock has “stayed still” despite improving fundamentals, management sees it as a good use of cash. However, they remain committed to M&A as the primary growth driver, with larger deals potentially meaningfully larger than Novari. The balance is delicate: buyback now, and larger transactions later.
Conclusion
The quarter was a validation of the playbook: acquire niche health-tech assets, cross-sell into existing client bases, and layer on AI features to drive ARPU. The $100M ARR milestone is a psychological marker that should help in both customer and investor conversations. With a strong balance sheet, a dedicated M&A pipeline, and an emerging AI revenue stream, Vitalhub is positioned to compound. The key risks remain the Palantir-related uncertainty in the U.K. and the execution of integrating Buddy while pushing organic growth. But the trajectory is clear: this is a company that is learning to grow efficiently and profitably.